WASHINGTON, June 29: Patients with a form of the chronic blood disorder hemophilia will soon have a new therapy that not only treats episodes of excessive bleeding, but helps to prevent them. The Food and Drug Administration on Thursday granted US marketing approval for Rixubis, a genetically engineered protein made by Baxter International Inc that represents the first new treatment for the genetic disorder in more than 15 years. (agencies)
Trending Now
E-Paper
Follow our WhatsApp channel